SKiN Centre for Dermatology, Peterborough, ON, Canada.
Probity Medical Research, Waterloo, ON, Canada.
Skin Therapy Lett. 2023 Sep;28(5):1-4.
Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and tolerability. It is non-steroidal, administered once-daily, and highly potent, with a unique delivery formulation. It can be used on most body areas, including the sensitive intertriginous regions and face. Herein, we review the safety and efficacy of roflumilast 0.3% cream, as demonstrated in clinical trials.
罗氟司特是一种高度选择性的磷酸二酯酶-4 抑制剂，用于治疗斑块状银屑病。罗氟司特 0.3%乳膏已获得美国 FDA 和加拿大卫生部批准，可用于青少年和成年人，具有良好的疗效和耐受性。它是一种非甾体药物，每日一次给药，具有高效性和独特的给药配方。它可用于大多数身体部位，包括敏感的皱褶部位和面部。本文综述了临床试验中罗氟司特 0.3%乳膏的安全性和疗效。
